Truist Securities analyst Joon Lee downgraded Editas Medicine (NASDAQ: EDIT) from Buy to Hold.The analyst comments: "Editas shared significant strategic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE